OpGen, Inc. (OPGN)
| Market Cap | 18.02M |
| Revenue (ttm) | 3.95M |
| Net Income (ttm) | -33.93M |
| Shares Out | 46.56M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 318,671 |
| Open | 0.390 |
| Previous Close | 0.389 |
| Day's Range | 0.380 - 0.410 |
| 52-Week Range | 0.310 - 3.720 |
| Beta | -0.51 |
| Analysts | Buy |
| Price Target | 3.57 (+822.5%) |
| Earnings Date | May 12, 2022 |
About OPGN
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also com...
Financial Performance
In 2021, OpGen's revenue was $4.31 million, an increase of 2.17% compared to the previous year's $4.21 million. Losses were -$34.81 million, 32.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for OPGN stock is "Buy." The 12-month stock price forecast is 3.57, which is an increase of 822.48% from the latest price.
News
OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OpGen Reports First Quarter 2022 Financial Results and Provides Business Update
ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to he...
OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2022...
OpGen's Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment
ROCKVILLE, Md., April 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectio...
OpGen's Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
New services include pathogen identification, microbiome profiling and rapid turnaround sequencing of clinical isolates New services include pathogen identification, microbiome profiling and rapid turna...
OpGen's subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions i...
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectio...
OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel
ROCKVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
ROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:3...
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and...
OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of C...
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...
OpGen Announces Successful Completion of Unyvero A30 Development Milestone
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...
OpGen to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...
OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update
ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infect...
OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents
ROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help...
OpGen Announces Results of Special Meeting of Stockholders
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help...
OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction
ROCKVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...
5 Penny Stocks To Buy Now According To Insiders In November 2021
Hot penny stocks insiders are buying in November The post 5 Penny Stocks To Buy Now According To Insiders In November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...
OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
Conference call to be held at 4:30 p.m. Eastern Standard Time today
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen Appoints Albert Weber as Chief Financial Officer
ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to h...
OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common...
ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help...
OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Easte...
ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2021 ...
OpGen Subsidiary Ares Genetics Launches AREScloud
ROCKVILLE, Md., Oct. 21, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectiou...
OpGen Announces Closing of $15 Million Registered Direct Offering
ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to h...